Evidence map›Paper›PMID 35985698›Full record

ArticleJournal of applied clinical medical physics2022

Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc.

Holly M Parenica Paschal, Christopher N Kabat, Pavlos Papaconstadopoulos, Neil A Kirby, Pamela A Myers, Timothy D Wagner, Sotirios Stathakis

Abstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Holly M Parenica PaschalDepartment of Radiation Oncology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID https://orcid.org/0000-0003-3984-1854
Christopher N KabatDepartment of Radiation Oncology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Pavlos PapaconstadopoulosThe Netherlands Cancer Institute, Amsterdam, The Netherlands.
Neil A KirbyDepartment of Radiation Oncology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Pamela A MyersDepartment of Radiation Oncology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Timothy D WagnerDepartment of Radiation Oncology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Sotirios StathakisDepartment of Radiation Oncology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Funding

NRSA Training Core (TL1)TL1TR002647 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUN, YONG-HEE PATRICIA, FREI, CHRISTOPHER R. · 2018 to 2022
$1.8M
Cancer Prevention and Research Institute of Texas RP170345NCATS NIH HHSNIH HHS TL1 TR002647
6 · The paper itself

Abstract

introductionNumerous studies have proven the Monte Carlo method to be an accurate means of dose calculation. Although there are several commercial Monte Carlo treatment planning systems (TPSs), some clinics may not have access to these resources. We present a method for routine, independent patient dose calculations from treatment plans generated in a commercial TPS with our own Monte Carlo model using free, open-source software. MATERIALS AND

methodsA model of the Elekta Versa HD linear accelerator was developed using the EGSnrc codes. A MATLAB script was created to take clinical patient plans and convert the DICOM RTP files into a format usable by EGSnrc. Ten patients' treatment plans were exported from the Monaco TPS to be recalculated using EGSnrc. Treatment simulations were done in BEAMnrc, and doses were calculated using Source 21 in DOSXYZnrc. Results were compared to patient plans calculated in the Monaco TPS and evaluated in Verisoft with a gamma criterion of 3%/2 mm.

resultsOur Monte Carlo model was validated within 1%/1-mm accuracy of measured percent depth doses and profiles. Gamma passing rates ranged from 82.1% to 99.8%, with 7 out of 10 plans having a gamma pass rate over 95%. Lung and prostate patients showed the best agreement with doses calculated in Monaco. All statistical uncertainties in DOSXYZnrc were less than 3.0%.

conclusionA Monte Carlo model for routine patient dose calculation was successfully developed and tested. This model allows users to directly recalculate DICOM RP files containing patients' plans that have been exported from a commercial TPS.

Indexed as

Particle AcceleratorsRadiotherapy Planning, Computer-AssistedAlgorithmsHumansMaleMonte Carlo MethodPhantoms, ImagingRadiotherapy DosageSoftwaredose calculationMonte Carloquality assurance

Identifiers

PMID35985698
PMCPMC9512349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.